More health professionals and patients now use AI to look up medicines: 72% of US doctors used AI for at least one task in 2026, up from 38% in 2023, and 32% of US adults used an AI chatbot for health. The report shows where AI appears when a medicine is chosen, and estimates the cost of a team supported by AI agents.
In the report
3 changes in how medicines are sold, with the evidence for each
Where AI appears when a medicine is chosen, and its known limits
The estimated cost of a team supported by AI agents, in a low, a main and a high case
Brands over 10 years old receive about 1.5% of their sales in promotion. EstimatedIQVIA, 2026
A team shared across brands and supported by AI agents costs an estimated 64.4% less per brand in the main case, and 2.6% less at worst. Estimated aikka cost model, report p. 26
Exhibits
Exhibit 6 of the report (p. 10). 48% of US millennials used AI for health; 12% of boomers. Source: Rock Health survey of 8,000 US adults, Dec. 2025. Measured.Exhibit 17 of the report (p. 22). AI already helps when a medicine is chosen and when it is approved. Source: JAMA, IQVIA, McKinsey, Bain and KLAS, Cohere Health, 2025 to 2026. Measured.Exhibit 23 of the report (p. 26). Estimated cost is 64.4% lower in the main case and 2.6% at worst. Source: aikka estimate, 2026. Estimated.
aikka builds AI-native commercialization for pharma. PharmaGEO, our entry product, shows brand teams what health professionals and patients ask AI tools about their medicines, and what the AI tools answer.